Amarin | AMRN - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 659.81M 10.31M 2025-09
AstraZeneca USD 114.07B 382M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
DBV Technologies USD 110.49M 32.93M 2025-09
Esperion Therapeutics USD 465.89M 101.87M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 107.29B 2.89B 2025-09